Please assess the completion status of the following clinical trial:

Trial Title: Normal Pressure Hydrocephalus Treatment by Acetazolamide

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Included will be subjects with a probable diagnosis of iNPH. The diagnosis will be based primarily on presence of gait impairment plus at least one other impairment in urinary symptoms, cognition impairment or both.~1. Are 60 years old or older~2. Patients who understand the study protocol~3. Patients who meet the criteria for NPH~   1. A typical personal history~  2. A typical brain imaging on head CT or MRI~  3. Normal LP findings excluding other conditions~  4. Exclusion of other conditions causing the symptomatology~  5. Patients who underwent Continuous lumbar drainage or spinal tap which improved symptomatology.~Exclusion Criteria:~1. Patients below the age of 60 years.~2. Patients who underwent shunt surgery~3. Patients with a concurrent diagnosis of a neurodegenerative or neurovascular disease that causes a significant impairment of gait and cognitive functions~4. Patients with symptom duration of more than 6 month~5. Patients with contraindications for acetazolamide treatment:~   * Cirrhosis or marked liver disease or dysfunction~  * hyperchloremic acidosis~  * hypersensitivity to acetazolamide or any component of the product~  * hypersensitivity to sulfonamides or other sulfonamide derivatives, as cross-sensitivity may occur~  * hypokalemia~  * hyponatremia~  * renal dysfunction or disease~  * suprarenal gland failure

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Acetazolamide (Type: ACTIVE_COMPARATOR): active comparator group will receives 500 mg azetazolamide daily
- sugar pill (Type: PLACEBO_COMPARATOR): placebo comparator group will receives placebo daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).